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Background: Tracking of replicative senescence is of fundamental relevance in cellular therapy. Cell
preparations – such as mesenchymal stromal cells (MSCs) - undergo continuous changes during culture expansion,
which is reflected by impaired proliferation and loss of differentiation potential. This process is associated with
epigenetic modifications: during in vitro culture, cells acquire senescence-associated DNA methylation (SA-DNAm)
changes at specific sites in the genome. We have recently described an Epigenetic-Senescence-Signature that
facilitates prediction of the state of cellular aging by analysis of DNAm at six CpG sites (associated with the genes
GRM7, CASR, PRAMEF2, SELP, CASP14 and KRTAP13-3), but this has not yet been proven over subsequent passages
and with MSCs isolated under good manufacturing practice (GMP) conditions.
Findings: MSCs were isolated from human bone marrow and GMP-conform expanded for up to 11 passages.
Cumulative population doublings (cPDs) and long-term growth curves were calculated based on cell numbers at
each passage. Furthermore, 32 cryopreserved aliquots of these cell preparations were retrospectively analyzed
using our Epigenetic-Senescence-Signature: DNAm-level was analyzed at six specific CpGs, and the results were
used to estimate cPDs, time of culture expansion, and passage numbers. Overall, predicted and real parameters
revealed a good correlation, particularly in cPDs. Based on predicted cPDs we could reconstruct long-term growth
curves and demonstrated the continuous increase in replicative senescence on molecular level.
Conclusion: Epigenetic analysis of specific CpG sites in the genome can be used to estimate the state of cellular
aging for quality control of therapeutic cell products.
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Mesenchymal stromal cells are usually culture expanded
for clinical application. Yet, cells undergo tremendous
changes during long-term culture: they enlarge, acquire
flat “fried-egg” morphology, lose differentiation potential,
and ultimately stop proliferation [1,2]. This phenomenon
has already been described over 50 years ago by Leonhard
Hayflick [3]. It is important to note that functional* Correspondence: wwagner@ukaachen.de
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article, unless otherwise stated.changes - including loss of colony-forming units, as well
as adipogenic and osteogenic differentiation potential -
become already evident during early passages [4]. There
is also evidence that secretory and immunomodulatory
functions of MSCs change upon in vitro expansion [5].
Furthermore, cells in culture may be more prone to
mutations – and hence, malignant transformation [6,7].
This conflicts with the high demands for standardization
and safety in regenerative medicine. Therefore, it is im-
portant to monitor replicative senescence in long-term
culture of MSCs [8].
Analysis of senescence-associated beta-galactosidase
(SA-β-Gal) activity is the most widely used biomarkerentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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it is particularly detected in very late, senescent passages
[10], although other authors indicated that it is also
up-regulated earlier in culture [11,12]. Furthermore,
SA-β-Gal may also be induced upon stress during
in vitro culture [13] but this analysis does not facilitate
reliable estimation of cumulative population doublings
(cPDs). Telomere attrition has also been correlated
with replicative potential, but the results vary between
different cell types and culture methods [14-16]. Ana-
lysis of cPDs necessitates precise cell counting at each
passage throughout culture expansion. So far, the state
of cellular aging could not be determined retrospectively
without this information.
Culture expansion of MSCs is associated with senescence-
associated DNA-methylation (SA-DNAm) changes at
specific sites in the genome which become either hyper-
methylated or hypo-methylated [17,18]. These senescence-
associated CpG sites are enriched in developmental genes
and they correlate with repressive histone marks [19]. The
mechanism regulating these SA-DNAm changes is yet un-
clear – it is possible that they resemble a kind of epigen-
etic drift, similar to observations in aging of the organism
[20]. On the other hand, we have recently demonstrated
that almost the entire set of SA-DNAm is reversed by re-
programming into induced pluripotent stem cells (iPSCs)
indicating that the process can be reversed by the pluripo-
tent state [21]. It is also unknown if SA-DNAm changes
entail the profound functional changes during culture
expansion, or if they rather resemble a byproduct. Either
way, SA-DNAm changes are highly reproducible and may
therefore be used to monitor cellular senescence. To this
end, we have elaborated an Epigenetic-Aging-Signature
based on six specific CpG sites which seemed to display
consistent SA-DNAm changes in different cell prepa-
rations. Integration of these DNAm levels in linear-
regression models facilitated prediction of passage
number, cPDs, and days of in vitro culture [22]. Yet,
this method required further validation – particularly
on cell preparations isolated under good manufacturing
practice (GMP) conditions. So far, the method has not
been used with cells isolated in serial passages and with
DNA directly isolated from cryopreserved cell aliquots.
Therefore, we performed the following retrospective
study:
MSCs were isolated from human bone marrow of the
iliac crest of three different heart patient donors after full
informed consent with ethical approval by the Ethical
Committee from the University Hospital Erasme of the
Université Libre de Bruxelles (ULB; aggregation number
N°OM021) and cultivated as described before [23]. In
brief, cells were cultured at 37°C in Advanced Minimal
Essential Medium (Invitrogen, Eugene, OR, USA) sup-
plemented with 5% human platelet lysate (Mill CreekLife Science, Rochester, MN, USA), Glutamax™ (Invitro-
gen), and penicillin/streptomycin (Invitrogen). After
24 h, non-adherent bone marrow and cellular debris
were removed and adherent mesenchymal cells were
expanded using cell seeding densities varying between
2,000 and 6,000 cells/cm2. After the initial passages
cultures were split into parallel subcultures, cultivated
for several passages and in some cases subcultured for a
second time (Figure 1A). Upon several amplification
rounds cells were treated with C3BS proprietary cardio-
trophic cocktail containing additional growth factors.
Post-cocktail treatment, cells were cultured for a mini-
mum of two additional passages or until growth arrest
was observed. At each passage, cell numbers and seed-
ing density have been carefully documented. Based on
these numbers we calculated long-term growth curves
(Figure 1B). MSCs of all three donors stopped prolifera-
tion after about 30 cPDs. Even when the culture was
split and further cultured independently, there was only
a slight deviation in the maximal number of cPDs which
might either be due to the outgrowth of different sub-
fractions or deviations in cell counting.
Thirty-two cryopreserved samples, which correspond to
various passages of the three donors, were then analyzed
using the Epigenetic-Senescence-Signature to estimate
the state of cellular aging. In our previous work, we did
not analyze many subsequent passages from the same
cell preparation and harvested DNA directly from cells
in culture. DNA was now isolated from cryopreserved
vials without taking cells into culture and then bisulfite-
converted. SA-DNAm of the six relevant CpGs was ana-
lyzed in a blinded manner by pyrosequencing as described
in detail before (performed at Varionostic GmbH, Ulm,
Germany) [22,24]. In brief, two CpGs become continu-
ously hyper-methylated in long-term culture (associated
with the genes GRM7 and CASR) and four CpGs become
hypo-methylated (corresponding to PRAMEF2, SELP,
CASP14 and KRTAP13-3). DNAm values of each sample
were then used for linear regression analysis to predict
cPDs, passage number and days of in vitro culture. An
online-calculator is provided under: http://www.molcell.
rwth-aachen.de/dms/. It needs to be noted that the genes
associated with the six relevant CpGs are not expressed in
MSCs [22]. In fact, there are highly reproducible changes
in gene expression profiles during long-term culture
[10,25] but this seems to be hardly related to SA-DNAm
changes [17,21]. Thus, there is no direct association of the
Epigenetic-Senescence-Signature with well-known path-
ways of senescence [26] – it is a suitable biomarker but
the functional relevance is yet unclear.
Overall, the predictions for cPDs, days of in vitro culture
and passage numbers correlated well with real parameters,
although they were slightly overestimated (Figure 1C).
The best correlation was observed with cPDs which may
Figure 1 Epigenetic-Senescence-Signature during long-term culture of MSCs. (A) MSCs were isolated form bone marrow (BM) of three patients
and sub-cultured during expansion as indicated by the hierarchical trees. (B) Long-term growth curves reveal that cell growth decayed within 30
cumulative population doublings (cPDs). Black triangles indicate subculturing as mentioned above. (C) DNAm analysis at six senescence-associated
CpG sites was then performed in various cryopreserved vials by pyrosequencing [22,24]. Based on these results we calculated predictions for cPDs, days
of in vitro culture and passage numbers. These predictions were subsequently compared to real values. (D) Predictions for cPDs, as determined using
the Epigenetic-Aging-Signature, were plotted against real culture time to simulate long-term growth curves. Overall, the results correspond to real
long-term growth curves even with regard to different subcultures (symbols as depicted in B).
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imprecise measure which is greatly affected by handling in
cell culture, whereas cultivation-time is interdependent on
donor-specific differences in cell growth. Overestimation
of the state of cellular aging might be attributed to oper-
ational procedures in cell culture or to systematic devi-
ation in cell counting. On the other hand, differences in
starting material and culture conditions may have signifi-
cant impact on replicative senescence during culture ex-
pansion, too, and this may necessitate further adaptationof the differential equations. Particularly samples of donor
3 revealed a low correlation and a different slope of pre-
dicted versus real parameters. This supports the notion
that there are differences in the state of cellular senescence
between cell preparations which are not necessarily
reflected by long-term growth curves. Subsequently, we
simulated long-term growth curves based on the predicted
values for cPDs. As mentioned above, different subcul-
tures reached slightly different maximal cPDs. The same
tendencies were also observed epigenetically: subcultures
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reached more cPDs using the Epigenetic-Aging-Signature
(Figure 1D). This indicates that the differences are
indeed cell-intrinsic and not due to deviations in cell
counting.
There is a growing perception that standardized pro-
tocols and quality control of therapeutic cell prepara-
tions are a prerequisite for reliable and reproducible
cellular therapy. Given the major impact of long-term
culture on molecular changes in MSCs it is very likely
that this process has also impact on the therapeutic po-
tential. Clinical outcome should therefore be evaluated
in the context of cellular aging. In this short report, we
provide further evidence that this can be tracked by spe-
cific epigenetic modifications. Epigenetic analysis may
be used as a tool to validate cell counts and sampling in
the course of long-term culture of MSCs – which is a
time consuming and error prone procedure – and it is
of particular relevance if detailed cell numbers have not
been documented throughout expansion. We demon-
strate that our Epigenetic-Senescence-Signature reflects
inter-individual differences and variation in subpopula-
tions which are not necessarily reflected in conventional
long-term growth curves. In this regard, the epigenetic
state of cell preparations might even provide the more
accurate measurement for the biological state of cellular
aging. Furthermore, it will be interesting to investigate
if molecules secreted by senescent cells, a phenomenon
termed senescence-associated secretory phenotype (SASP),
affect also the epigenetic state of cells in culture [27,28].
Our method facilitates analysis of continuously cultured
cells as well as retrospective analysis of cryopreserved re-
sidual vials [22]. Cryopreservation is commonly performed
in many labs and clinical trials – even though this process
makes a selection because, after thawing, not all cells grow
out. On the other hand, applicability on such retained
samples, which are usually collected in clinical trials, now
opens new perceptive to gain better insight in the impact
of long-term culture on clinical outcome. In the future, it
would therefore be interesting to analyze SA-DNAm sam-
ples in therapeutic cellular products and to correlate the
results with clinical performance.Abbreviations
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